NeuroDerm Company Profile (NASDAQ:NDRM)

About NeuroDerm (NASDAQ:NDRM)

NeuroDerm logoNeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NDRM
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.02 billion
  • Outstanding Shares: 26,346,000
Average Prices:
  • 50 Day Moving Avg: $38.84
  • 200 Day Moving Avg: $32.05
  • 52 Week Range: $15.20 - $38.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.92
  • P/E Growth: -0.83
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.87 per share
  • Price / Book: 7.98
  • EBITDA: ($49,040,000.00)
  • Return on Equity: -38.82%
  • Return on Assets: -36.88%
  • Current Ratio: 17.69%
  • Quick Ratio: 17.69%
  • Average Volume: 807,554 shs.
  • Beta: 0.77
  • Short Ratio: 1.47

Frequently Asked Questions for NeuroDerm (NASDAQ:NDRM)

What is NeuroDerm's stock symbol?

NeuroDerm trades on the NASDAQ under the ticker symbol "NDRM."

How were NeuroDerm's earnings last quarter?

NeuroDerm Ltd. (NASDAQ:NDRM) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.25) EPS for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.13. View NeuroDerm's Earnings History.

When will NeuroDerm make its next earnings announcement?

NeuroDerm is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for NeuroDerm.

Where is NeuroDerm's stock going? Where will NeuroDerm's stock price be in 2017?

8 analysts have issued 12-month price objectives for NeuroDerm's stock. Their forecasts range from $39.00 to $70.00. On average, they anticipate NeuroDerm's stock price to reach $45.86 in the next year. View Analyst Ratings for NeuroDerm.

What are analysts saying about NeuroDerm stock?

Here are some recent quotes from research analysts about NeuroDerm stock:

  • 1. According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (10/18/2017)
  • 2. Cowen and Company analysts commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the initial feedback from our consultants has been very positive. In general, our consultants believe the efficacy looks comparable to Duodopa, but with a significantly improved use and safety profile. These data substantially de-risk the program. The current valuation is dramatically understated." (3/1/2017)

Are investors shorting NeuroDerm?

NeuroDerm saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,221,573 shares, an increase of 28.1% from the August 31st total of 953,489 shares. Based on an average daily trading volume, of 530,756 shares, the short-interest ratio is presently 2.3 days. Approximately 6.0% of the shares of the stock are sold short.

Who are some of NeuroDerm's key competitors?

Who are NeuroDerm's key executives?

NeuroDerm's management team includes the folowing people:

  • Robert Taub, Chairman of the Board
  • Oded S. Liebermann, Chief Executive Officer, Director
  • Roy Golan CPA, Chief Financial Officer
  • Tami Yardeni, Chief Operating Officer
  • Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
  • Sheila Oren, Vice President - Clinical and Regulatory Affairs
  • Eran Shor, Vice President - Devices
  • Oron Yacoby-Zeevi, Vice President - Research & Development
  • Revital Mandil-Levin Ph.D., Head - Business Development
  • Shmuel Cabilly, Director

When did NeuroDerm IPO?

(NDRM) raised $45 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

How do I buy NeuroDerm stock?

Shares of NeuroDerm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeuroDerm's stock price today?

One share of NeuroDerm stock can currently be purchased for approximately $38.85.

MarketBeat Community Rating for NeuroDerm (NASDAQ NDRM)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about NeuroDerm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeuroDerm (NASDAQ:NDRM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $45.86 (18.04% upside)
Consensus Price Target History for NeuroDerm (NASDAQ:NDRM)
Price Target History for NeuroDerm (NASDAQ:NDRM)
Analysts' Ratings History for NeuroDerm (NASDAQ:NDRM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Jefferies Group LLCReiterated RatingBuy$42.00LowView Rating Details
8/2/2017Roth CapitalDowngradeBuy -> Neutral$33.00 -> $39.00LowView Rating Details
7/24/2017Raymond James Financial, Inc.DowngradeOutperform -> Market Perform$39.00HighView Rating Details
7/21/2017Deutsche Bank AGInitiated CoverageBuy -> Buy$47.00HighView Rating Details
6/14/2017CIBCUpgradeMarket Perform -> Outperform$42.00HighView Rating Details
6/14/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> Outperform$42.00HighView Rating Details
3/7/2017Citigroup Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/1/2017Cowen and CompanyBoost Price TargetOutperform$38.00 -> $70.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for NeuroDerm (NASDAQ:NDRM)
Earnings by Quarter for NeuroDerm (NASDAQ:NDRM)
Earnings History by Quarter for NeuroDerm (NASDAQ NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.38)($0.25)ViewN/AView Earnings Details
3/30/201712/31/2016($0.46)($0.49)ViewN/AView Earnings Details
11/10/20169/30/2016($0.42)($0.42)ViewN/AView Earnings Details
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)($0.31)ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.07)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015Q4 2014($0.35)($2.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeuroDerm (NASDAQ:NDRM)
2017 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.40)($0.40)($0.40)
Q2 20172($0.51)($0.40)($0.46)
Q3 20172($0.58)($0.50)($0.54)
Q4 20172($0.62)($0.50)($0.56)
(Data provided by Zacks Investment Research)


Dividend History for NeuroDerm (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NeuroDerm (NASDAQ:NDRM)
No insider trades for this company have been tracked by


Headline Trends for NeuroDerm (NASDAQ:NDRM)
Latest Headlines for NeuroDerm (NASDAQ:NDRM)
DateHeadline logoMitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release) - October 19 at 6:40 AM logoMitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - October 18 at 4:46 AM logoZacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per Share - October 15 at 12:08 AM logoZacks Investment Research Downgrades Neuroderm Ltd (NDRM) to Sell - October 8 at 11:50 PM logoCritical Review: NeuroDerm (NDRM) versus Its Competitors - October 2 at 2:22 AM logoNeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by Analysts - September 30 at 10:42 AM logoNeuroDerm Ltd. (NDRM) Short Interest Update - September 30 at 3:26 AM logoNeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release) - September 14 at 8:11 AM logoNeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - September 13 at 7:01 AM logoNeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by Analysts - September 5 at 10:44 AM logoNeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in August - August 29 at 1:06 AM logoStocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release) - August 23 at 9:05 AM logoEquities Analysts Offer Predictions for NeuroDerm Ltd.'s Q3 2017 Earnings (NDRM) - August 18 at 6:42 AM logoNeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLC - August 14 at 6:06 AM logoNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from Brokerages - August 11 at 6:18 PM logoNeuroDerm Announces Second Quarter 2017 Financial Results - August 4 at 6:15 AM logoRoth Capital Downgrades NeuroDerm Ltd. (NDRM) to Neutral - August 2 at 8:44 AM logoNeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation - August 2 at 6:14 AM logoNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - Nasdaq - July 27 at 4:43 AM logoFeatured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp. - July 27 at 4:43 AM logoNeuroDerm (NDRM) Agrees to be Acquired by Japan's Mitsubishi Tanabe Pharma for $1.1B - July 26 at 4:02 AM logoNeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe Pharma - July 26 at 4:02 AM logoNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - July 26 at 4:01 AM logoBiotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - - July 25 at 6:04 AM logoNeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - Nasdaq - July 25 at 6:04 AM logoJapan's Nikkei inches up, caught in tight range before Fed meeting - July 25 at 6:04 AM logoAussie stocks lead a rebound for Asian markets as dollar steadies - July 25 at 6:04 AM logoNikkei edges down before Fed; Topix ends below key technical level - July 25 at 6:04 AM logoNeuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform" - July 24 at 2:52 PM logoNeuroDerm To Be Bought By Japan's Mitsubishi Tanabe Pharma For $1.1 Blm In Cash - July 24 at 7:10 AM logoNeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash - July 24 at 7:10 AM logoMitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln - July 24 at 7:10 AM logoNeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AG - July 22 at 8:14 PM logoDeutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - - July 22 at 6:50 AM logoMarket Limps Into Weekend - July 22 at 6:50 AM logoNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from Analysts - July 17 at 11:59 AM logoNeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per Share - July 10 at 2:15 PM logoResults of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology - June 27 at 7:55 AM logoFirm Fighting Parkinson's Hails Reviews, Upgrade - June 14 at 10:44 PM logoGainers & Losers Of June 14: OMER, EPZM, ALXN, SBBP, GBT... - June 14 at 10:44 PM logoNeuroDerm (NDRM) Design of ND0612 Phase III iNDiGO Efficacy ... - - June 6 at 7:29 PM logoNeuroDerm (NDRM) Presents ND0612H Phase II Trial Results in Late-Breaking Poster at MDS Congress - - June 6 at 12:25 AM logoNeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster ... - June 5 at 7:24 PM logoNeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017 - GlobeNewswire (press release) - May 30 at 7:06 AM logoNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - - May 24 at 6:53 PM logoNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - May 24 at 10:29 AM logoNeuroDerm reports 1Q loss - May 11 at 9:28 AM logoNeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq - April 22 at 6:11 PM logoQ4 2016 Neuroderm Ltd Earnings Release - Before Market Open - March 30 at 7:05 PM logoNeuroDerm downgraded by Oppenheimer - March 7 at 6:37 PM



NeuroDerm (NDRM) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.